Zephyr AI

And that’s a wrap! We had a fantastic experience at the 2025 AI Drug Discovery & Development Summit. 👏 Our Chief Business and Clinical Officer, Anshu Jain, delivered his session, highlighting how "leveraging real-world data enables us to build predictive models that go beyond black-box outputs and provide meaningful biological interpretability." We connected with so many inspiring innovators and collaborators across the field. The conversations reinforced our shared commitment to tackling the industry’s biggest challenges, and we look forward to continuing to push the boundaries of precision oncology together. #AIDrugDiscovery #PrecisionOncology #RealWorldData #AIinHealthcare

Zephyr AI is officially set up and ready for you at AIDDD — Booth 6! 🤝⚡️ We’re excited to connect with leaders across biopharma and diagnostics and share how we’re transforming complex, multimodal real-world data into scalable, patient-level insights. Let’s build together! #AIDDD #ZephyrAI #RealWorldData #MachineLearning #Partnerships #Innovation #TechTogether

Excited to join the AI Drug Discovery & Development Summit this week! 🔬💡 We look forward to connecting with fellow innovators to explore today’s challenges and the growing potential of #machinelearning and #AI in advancing precision medicine. 📍 Visit us at Booth #6 to meet the Zephyr AI team and see how we’re driving data-powered innovation in healthcare.

Thank you AI Drug Discovery & Development Summit for sharing! At Zephyr AI, we’re thrilled to amplify this powerful conversation around AI-driven drug discovery and clinical trials. What stands out? The growing momentum of the pharmaceutical and biotech ecosystem embracing AI to not just accelerate timelines, but to fundamentally re-imagine how we discover, develop, and deploy therapies to the right patients at the right time. Our very own Anshu Jain will be presenting his “Hidden Insights: Supercharging the Potential of Real-World Data in Precision Oncology through AI” on Wednesday, November 19, 2025 from 3:00 PM to 3:30 PM. We hope to see you there! 👋

Transforming Cancer Care Through the Power of AI and Real-World Data 🚀 We’re excited to share that Zephyr AI has entered a strategic partnership with Guardant Health, a global leader in precision oncology. Together, we aim to unlock drug-response predictions and biomarker insights that can accelerate the next generation of cancer research and care. By combining Zephyr’s multimodal AI platform and real-world data capabilities with Guardant’s industry-leading diagnostics and molecular datasets, this collaboration will enable the development of interpretable, data-driven models that support biopharma innovation, targeted therapy selection, and response monitoring. At Zephyr, we envision a future where precision medicine is accessible and effective—guided by biologically grounded insights unique to each patient. Our AI platform transforms complex clinical and molecular data into meaningful solutions that drive discovery and better outcomes. This partnership embodies our shared belief that AI-driven integration of multimodal and real-world data can bridge diagnostics and therapeutics—advancing biomarker discovery and driving more precise, personalized cancer treatment. Read the full announcement below 👇 #PrecisionOncology #AIinHealthcare #DrugDevelopment #Biomarkers #LiquidBiopsy #CancerResearch #RealWorldData #Partnership #AI

Our new website is live! 🚀 Visit zephyrai.bio to explore how Zephyr AI is transforming real-world data into predictive insights that advance precision medicine. The redesigned site highlights our evolution as a company—where multi-modal AI meets clinical reality to power drug response modeling, clinical inference, and data-driven discovery. #PrecisionOncology #AIinHealthcare #RealWorldData #DrugDevelopment #Innovation

🎀 October is Breast Cancer Awareness Month. Breast cancer is the most commonly diagnosed cancer in women, with ~1 in 8 women expected to be diagnosed in their lifetime. Awareness and early detection matter—talk to your clinician about screening (mammograms save lives), discuss your family history and risk factors, and ask whether genetic testing is appropriate. Early, informed decisions can change outcomes: when breast cancer is found at a localized stage, the 5-year relative survival rate is >99% (American Cancer Society). #BreastCancerAwareness #WomensHealth #PrecisionOncology #AIinHealthcare #EarlyDetection

September is Prostate Cancer Awareness Month. At Zephyr AI, we stand with the community and are committed to advancing precision oncology. By harnessing AI and real-world data, we aim to uncover insights that bring clarity to complexity and move us closer to a future where every patient can access more personalized care. 💙 Early detection saves lives 🔍 Innovation can’t wait 👉 Learn more: https://lnkd.in/dTX2krxv #ProstateCancerAwareness #EarlyDetection #AIInHealthcare

Exciting news at Zephyr AI: We are welcoming Dr. Allen Chao, founder of Watson Pharmaceuticals, as our new CEO and announcing the acquisition of Aster Insights. Together, we are delivering real-world data, AI technology, and insights to transform precision medicine in oncology. Read more in our press release: https://bit.ly/4g3P4x6 #ZephyrAI #RealWorldData #AIinHealthcare #BiotechNews

🚨 JUST PUBLISHED 🚨 Our team’s latest work in Next Research Journal: "Semaglutide and Cardiovascular Outcomes in Overweight or Obesity Without Diabetes: A real-world cohort study." Why this matters: 💥 First large-scale real-world evidence of semaglutide’s impact on CV outcomes in low-risk patients 🧠 76,000 matched patients, no diabetes or prior CVD ❤️ 27% reduction in MI, stroke, or all-cause death 📉 Number needed to treat (NNT) = 200 — small individual effect, big population impact This study expands on SELECT trial findings and suggests that GLP-1 therapies may offer meaningful preventive cardiovascular benefit even in lower-risk populations. It also underscores the value of using harmonized claims data to derive timely, actionable insights at scale. Massive credit to our clinical and data science teams for driving this forward. This is exactly the kind of precision prevention work that defines Zephyr AI. We're excited to keep building. Read the paper here: https://lnkd.in/gBa5HCPw #ZephyrAI #RealWorldEvidence #CardiometabolicHealth #PrecisionMedicine #GLP1 #PopulationHealth #AIinHealthcare